These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Inhibition of the renin angiotensin system in pregnancy and risk of fetal malformations]. Lonati C, Morganti A. Pediatr Med Chir; 2009; 31(3):137-9. PubMed ID: 19739495 [No Abstract] [Full Text] [Related]
5. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G. J Obstet Gynaecol; 2011 Aug; 31(6):465-72. PubMed ID: 21823839 [Abstract] [Full Text] [Related]
6. [The use of angiotensin converting enzyme (ACE) inhibitors during pregnancy clearly increases the risk of congenital malformations]. de Leeuw PW. Ned Tijdschr Geneeskd; 2006 Jul 22; 150(29):1605-7. PubMed ID: 16901062 [Abstract] [Full Text] [Related]
7. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Bos-Thompson MA, Hillaire-Buys D, Muller F, Dechaud H, Mazurier E, Boulot P, Morin D. Ann Pharmacother; 2005 Jan 22; 39(1):157-61. PubMed ID: 15590878 [Abstract] [Full Text] [Related]
8. Beyond ONTARGET: angiotensin-converting enzyme inhibition and angiotensin II receptor blockade in combination, a lesser evil in some? Wong J, Molyneaux L, Constantino M, Twigg SM, Yue DK. Diabetes Obes Metab; 2010 Dec 22; 12(12):1072-8. PubMed ID: 20977578 [Abstract] [Full Text] [Related]
9. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Schaefer C. Birth Defects Res A Clin Mol Teratol; 2003 Aug 22; 67(8):591-4. PubMed ID: 14632309 [Abstract] [Full Text] [Related]
11. [Hypertension in pregnancy. ACE inhibitors and angiotensin II receptor antagonists are contraindicated because of their potential fetotoxicity]. Partosch F, Stahlmann R. Med Monatsschr Pharm; 2011 Oct 22; 34(10):358-62. PubMed ID: 22010419 [No Abstract] [Full Text] [Related]
12. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy--United States, Canada, and Israel, 1987-1995. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep; 1997 Mar 21; 46(11):240-2. PubMed ID: 9082178 [Abstract] [Full Text] [Related]
13. Antihypertensive drugs and the risk of prostate cancer. Morote J, Planas J. Eur Urol; 2011 Dec 21; 60(6):1309-10. PubMed ID: 21962717 [No Abstract] [Full Text] [Related]
14. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Quan A. Early Hum Dev; 2006 Jan 21; 82(1):23-8. PubMed ID: 16427219 [Abstract] [Full Text] [Related]
16. Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature. Enzensberger C, Eskef K, Schwarze A, Faas D, Axt-Fliedner R. Ultraschall Med; 2012 Oct 21; 33(5):493-6. PubMed ID: 21630188 [No Abstract] [Full Text] [Related]